Tags

Type your tag names separated by a space and hit enter

The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections.

Abstract

BACKGROUND

A well established drug for the treatment of asthma and allergy, sodium cromoglycate, was found in open trials to be useful as a symptomatic treatment for upper respiratory tract infections.

OBJECTIVE

To compare the efficacy of inhaled and intranasal sodium cromoglycate and matching placebos on the symptoms of upper respiratory tract infections.

METHODS

Adult subjects with symptoms of runny nose, throat pain, or cough for less than 24 h were recruited. They were treated for 7 days using a randomized, double-blind, placebo-controlled, group comparative design. The medication given was: sodium cromoglycate dry powder 20 mg per inhalation in spincaps; sodium cromoglycate aqueous nasal spray delivering 5.2 mg per dose; or matching placebo as dry powder and nasal spray. One spincap and one spray per nostril were taken every 2 h during waking hours on days 1 and 2 and then four times daily on days 3-7. Severity of nine symptoms (general malaise, body aches and pains, chills and shivering, sneezing, nasal running, nasal blocking, sore throat, cough and voice disturbance) was recorded twice daily by subjects on diary cards, using a scale of 0 (absent) to 3 (severe).

RESULTS

The study was conducted between February and April 1993. One hundred and eighteen patients aged 21-63 years (mean 41 years) were included. Symptoms resolved faster (P < 0.001) and the severity in the last three days of treatment was significantly less in patients treated with sodium cromoglycate than with placebo (P < 0.05-day 5; P < 0.01-day 6; P < 0.001-day 7). Side effects were local and mild and did not differ between the treatment groups.

CONCLUSION

Sodium cromoglycate administered both by inhalation and intranasally is an effective treatment for the symptoms of upper respiratory tract infection. Its combined safety and efficacy would make it an acceptable form of treatment for these conditions.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Paediatrics, University of Göteborg, East Hospital, Sweden.

    ,

    Source

    MeSH

    Administration, Inhalation
    Administration, Intranasal
    Adolescent
    Adult
    Anti-Asthmatic Agents
    Common Cold
    Cromolyn Sodium
    Double-Blind Method
    Female
    Humans
    Male
    Middle Aged
    Nebulizers and Vaporizers
    Powders
    Respiratory Tract Infections
    Treatment Outcome

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    8889259

    Citation

    Aberg, N, et al. "The Effect of Inhaled and Intranasal Sodium Cromoglycate On Symptoms of Upper Respiratory Tract Infections." Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 26, no. 9, 1996, pp. 1045-50.
    Aberg N, Aberg B, Alestig K. The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections. Clin Exp Allergy. 1996;26(9):1045-50.
    Aberg, N., Aberg, B., & Alestig, K. (1996). The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 26(9), pp. 1045-50.
    Aberg N, Aberg B, Alestig K. The Effect of Inhaled and Intranasal Sodium Cromoglycate On Symptoms of Upper Respiratory Tract Infections. Clin Exp Allergy. 1996;26(9):1045-50. PubMed PMID: 8889259.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections. AU - Aberg,N, AU - Aberg,B, AU - Alestig,K, PY - 1996/9/1/pubmed PY - 1996/9/1/medline PY - 1996/9/1/entrez SP - 1045 EP - 50 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin. Exp. Allergy VL - 26 IS - 9 N2 - BACKGROUND: A well established drug for the treatment of asthma and allergy, sodium cromoglycate, was found in open trials to be useful as a symptomatic treatment for upper respiratory tract infections. OBJECTIVE: To compare the efficacy of inhaled and intranasal sodium cromoglycate and matching placebos on the symptoms of upper respiratory tract infections. METHODS: Adult subjects with symptoms of runny nose, throat pain, or cough for less than 24 h were recruited. They were treated for 7 days using a randomized, double-blind, placebo-controlled, group comparative design. The medication given was: sodium cromoglycate dry powder 20 mg per inhalation in spincaps; sodium cromoglycate aqueous nasal spray delivering 5.2 mg per dose; or matching placebo as dry powder and nasal spray. One spincap and one spray per nostril were taken every 2 h during waking hours on days 1 and 2 and then four times daily on days 3-7. Severity of nine symptoms (general malaise, body aches and pains, chills and shivering, sneezing, nasal running, nasal blocking, sore throat, cough and voice disturbance) was recorded twice daily by subjects on diary cards, using a scale of 0 (absent) to 3 (severe). RESULTS: The study was conducted between February and April 1993. One hundred and eighteen patients aged 21-63 years (mean 41 years) were included. Symptoms resolved faster (P < 0.001) and the severity in the last three days of treatment was significantly less in patients treated with sodium cromoglycate than with placebo (P < 0.05-day 5; P < 0.01-day 6; P < 0.001-day 7). Side effects were local and mild and did not differ between the treatment groups. CONCLUSION: Sodium cromoglycate administered both by inhalation and intranasally is an effective treatment for the symptoms of upper respiratory tract infection. Its combined safety and efficacy would make it an acceptable form of treatment for these conditions. SN - 0954-7894 UR - https://www.unboundmedicine.com/medline/citation/8889259/full_citation L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0954-7894&amp;date=1996&amp;volume=26&amp;issue=9&amp;spage=1045 DB - PRIME DP - Unbound Medicine ER -